Human medicines European public assessment report (EPAR): Caprelsa, vandetanib, Date of authorisation: 16/02/2012, Revision: 32, Status: Authorised

Human medicines European public assessment report (EPAR): Vantobra (previously Tobramycin PARI), tobramycin, Date of authorisation: 18/02/2019, Revision: 7, Status: Authorised

Human medicines European public assessment report (EPAR): Kisqali, ribociclib, Date of authorisation: 22/08/2017, Revision: 27, Status: Authorised

Human medicines European public assessment report (EPAR): Loqtorzi, toripalimab, Date of authorisation: 19/09/2024, Revision: 5, Status: Authorised

Human medicines European public assessment report (EPAR): Silapo, epoetin zeta, Date of authorisation: 18/12/2007, Revision: 18, Status: Authorised

Human medicines European public assessment report (EPAR): Elmiron, pentosan polysulfate sodium, Date of authorisation: 02/06/2017, Revision: 15, Status: Authorised

Human medicines European public assessment report (EPAR): Obodence, denosumab, Date of authorisation: 12/02/2025, Revision: 5, Status: Authorised

Human medicines European public assessment report (EPAR): Bimervax, COVID-19 Vaccine (recombinant, adjuvanted), Date of authorisation: 30/03/2023, Revision: 16, Status: Authorised

Orphan designation: mavorixafor Treatment of WHIM syndrome, 25/07/2019 Positive

Human medicines European public assessment report (EPAR): Dzuveo, sufentanil, Date of authorisation: 25/06/2018, Revision: 9, Status: Authorised